Veytics Intelligence
2026-09-15 · Yahoo

Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback

Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Przeczytaj pelny brief Veytics

Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.